Laboratory parameters of hemostasis in patients with covid-19

Abstract

The new coronavirus infection (currently classified as COVID-19), first identified in December 2019 in Wuhan, China, has contributed to a significant increase in global mortality. Coagulopathy is a common disorder in COVID-19 patients, which develops in parallel with respiratory failure. Currently, COVID-19 continues to be a life-threatening disease and requires new developments and solutions to define preventive and curative strategies. Studies often report an abnormality in the balance of coagulation and fibrinolytic systems in COVID-19, but there is still no adequate set of laboratory tests that could provide a diagnosis of coagulopathy in COVID-19. This review analyzes current studies on the clinical manifestations of COVID-19 coagulopathy, and also analyzes the informativeness of laboratory hemostasis tests in relation to the severity of the disease and clinical outcomes.